|
|
CLASSIF1 Classification |
- Patient stratification provides prognostic information for
the future of patient groups or cohorts
(L1)
but no
individualized
outcome prediction
(
L2)
as obtained by data pattern classification..
(fig.3,
fig.4).
- Prognostic and
individually predictive
data patterns show only partial identity (CD4, CD11b, CD13, HLA-DR),
characterizing the difference between group prognostic
stratification (fig.6) and
individualized predictions.
Literature References:
L1.
Repp R, Schaekel U, Helm G, Thiede C, Soucek S, Pascheberg U,
Wandt H, Aulitzky W, Bodenstein H, Kuse R, Link H, Ehninger G,
Gramatzki M and AML-SHG Study
Immunophenotyping is an independent factor for risk stratification
in AML.
Cytometry 53B:11-19, (2003)
L2.
Valet G, Repp R, Link H, Ehninger G, Gramatzki M and
SHG-AML study group.
Pretherapeutic identification of high risk acute myeloid leukemia (AML)
patients from immunophenotype, cytogenetic and clinical parameters.
Cytometry 53B:4-10, (2003)
| © 2025 G.Valet |